Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
暂无分享,去创建一个
G. Braunstein | S. Gery | R. Okamoto | J. Said | Yan Zhou | J. Gu | H. Phillip Koeffler | S. Miles | Conghui Zhao | Rocio Alvarez | N. Doan | Ryoko Okamoto | Phillip Koeffler
[1] Ryohei Katayama,et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. , 2013, Cancer research.
[2] A. Bardelli,et al. Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET , 2013, Clinical Cancer Research.
[3] W. Birchmeier,et al. Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.
[4] K. Al-Kuraya,et al. c-Met Inhibitor Synergizes with Tumor Necrosis Factor-Related Apoptosis-Induced Ligand to Induce Papillary Thyroid Carcinoma Cell Death , 2012, Molecular medicine.
[5] N. Senzer,et al. A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors , 2011, Clinical Cancer Research.
[6] D. Collins,et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] L. Trusolino,et al. MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.
[8] J. Copland,et al. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).
[9] S. Jeay,et al. ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity , 2010, Molecular Cancer Therapeutics.
[10] D. Bottaro,et al. Targeting the HGF/Met signalling pathway in cancer. , 2010, European journal of cancer.
[11] M. Ladanyi,et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.
[12] G. V. Vande Woude,et al. Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer , 2009, Clinical Cancer Research.
[13] Christopher Korch,et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. , 2008, The Journal of clinical endocrinology and metabolism.
[14] Gary L Clayman,et al. Small molecule c‐MET inhibitor PHA665752: Effect on cell growth and motility in papillary thyroid carcinoma , 2008, Head & neck.
[15] Shinji Yamazaki,et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.
[16] Mieke Schutte,et al. Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines , 2007, Molecular Cancer Research.
[17] G. Braunstein,et al. Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivo , 2006, Clinical Cancer Research.
[18] A. Costantino,et al. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. , 2004, Endocrinology.
[19] A. Pasquini,et al. Increased expression of Met protein is associated with up‐regulation of hypoxia inducible factor‐1 (HIF‐1) in tumour cells in papillary carcinoma of the thyroid , 2004, The Journal of pathology.
[20] F. Meric,et al. Expression profile of tyrosine kinases in breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] J. Samet,et al. Food and Drug Administration , 2007, BMJ : British Medical Journal.
[22] C Eng,et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[23] T. Ståhl,et al. Non-autocrine, constitutive activation of Met in human anaplastic thyroid carcinoma cells in culture , 1999, British Journal of Cancer.
[24] P. Comoglio,et al. Expression of Met protein and urokinase‐type plasminogen activator receptor (uPA‐R) in papillary carcinoma of the thyroid , 1998, The Journal of pathology.
[25] F. Trimarchi,et al. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. , 1998, Thyroid : official journal of the American Thyroid Association.
[26] P. Comoglio,et al. EXPRESSION OF Met PROTEIN IN THYROID TUMOURS , 1996, The Journal of pathology.
[27] M. Pierotti,et al. Overexpression of the C-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium , 1995, Journal of endocrinological investigation.
[28] W. Bodmer,et al. p53 mutations in colorectal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.